Prediction of BK Virus Reactivation in Kidney Transplant Recipient

N/ACompletedNCT06219616

King Chulalongkorn Memorial Hospital80 enrolled

Overview

There has been no effective predicting tool to accurately predict BKV reactivation after kidney transplantation. The aim is to elucidate the use of flow cytometric analysis for both intracellular cytokines and surface activation markers for BKV-specific T cell response in kidney transplant recipients.

Study Type

INTERVENTIONAL

Allocation

Purpose

SCREENING

Masking

NONE

Enrollment

Conditions

Kidney Transplant Infection BK Virus Infection BK Virus Nephropathy

Interventions

BKV immune monitoringDIAGNOSTIC_TEST

Blood will be drawn and investigated for BKV-specific T cell response.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion criteria: 1. New kidney transplantation cases (either living donor or deceased donor transplantation) 2. Age ≥ 18 years old 3. Agree to give a permission to blood sampling post-transplantation, and at the time of BK viremia. Exclusion criteria: 1. Pregnant 2. Primary non-function of kidney allograft (i.e. kidney allograft never function).

Locations (1)

King Chulalongkorn Memorial Hospital

Bangkok, Bangkok, Thailand

Outcomes

Primary Outcomes

BKV-specific immune response

\- To examine the capability of flow cytometry in predicting post-kidney transplant BKV infection, by the analyses of intracellular cytokines (interleukine-2) and surface activation markers (CD25) of T cells

Time frame: Day 30, Day 90 after transplantation before BK viremia

Secondary Outcomes

Dynamic change of BKV-specific immune response

To examine the chonological change of BKV-specific immune response after transplantation, by the analyses of intracellular cytokines (interleukine-2) and surface activation markers (CD25) of T cells.

Time frame: Day 30, Day 90 after transplantation, irrespective ly to BK viremia

BKV-specific immune response and immunosuppression regimen

To examine the association between immunosuppressive regimen (tacrolimus, cyclosporine A, mycophenolate) and BKV-specific immune response after transplantation, by the analyses of intracellular cytokines (interleukine-2) and surface activation markers (CD25) of T cells.

Time frame: Day 30, Day 90 after transplantation, in correlation to immunosuppressive medications

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.